Finance

Lists
500660:BOM
GlaxoSmithKline Pharmaceuticals Ltd
₹2,512.40
-1.06%
(-27.00) 1D
Oct 15, 2:19:17 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 500660...
Open
₹2,550.00
High
₹2,550.00
Low
₹2,489.60
Mkt. cap
425.41B
Avg. vol.
5.03K
Volume
2.16K
Dividend
2.27%
Quarterly dividend
₹14.25
Ex-dividend date
May 29, 2026
P/E ratio
39.85
52-wk high
₹3,121.10
52-wk low
₹2,088.00
EPS
₹63.05
Shares outstanding
169.41M
No. of employees
3K
Open
₹2,550.00
High
₹2,550.00
Low
₹2,489.60
Mkt. cap
425.41B
Avg. vol.
5.03K
Volume
2.16K
Dividend
2.27%
Quarterly dividend
₹14.25
Ex-dividend date
May 29, 2026
P/E ratio
39.85
52-wk high
₹3,121.10
52-wk low
₹2,088.00
EPS
₹63.05
Shares outstanding
169.41M
No. of employees
3K
News stories
From web sources and news partners
Profile
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, and others. Wikipedia
About GlaxoSmithKline Pharmaceuticals Ltd
CEO-
Employees3.1K
FoundedNov 13, 1924
Headquarters-
SectorPharmaceutical industry
Websiteindia-pharma.gsk.com
Last report
Aug 3, 2026
Fiscal period
Q1 2027
₹14.00 / ₹13.90
+0.72%beat
Revenue / Est. (INR)
9.38B / 9.11B
+3.00%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
9.80B
10.41B
9.95B
9.38B
Cost of goods sold
3.56B
3.64B
3.69B
3.28B
Cost of revenue
3.56B
3.64B
3.69B
3.28B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.38B
1.52B
2.95B
1.59B
Operating expense
3.06B
3.26B
2.84B
3.31B
Total operating expenses
6.62B
6.90B
6.53B
6.59B
Operating income
3.18B
3.51B
3.43B
2.80B
Other non operating income
335.70M
321.20M
-1.09B
437.60M
EBT including unusual items
3.54B
4.00B
3.73B
3.22B
EBT excluding unusual items
3.51B
3.82B
2.94B
3.22B
Income tax expense
965.10M
1.04B
952.41M
852.70M
Effective tax rate
27.26%
26.08%
25.53%
26.44%
Other operating expenses
1.51B
1.54B
-236.82M
1.56B
Net income
2.57B
2.96B
2.78B
2.37B
Net profit margin
26.28%
28.39%
27.92%
25.27%
Earnings per share
-
-
-
14.00
Interest and investment income
-
-
657.30M
-
Interest expense
-5.10M
-11.90M
-6.12M
-9.70M
Net interest expenses
-5.10M
-11.90M
651.18M
-9.70M
Depreciation and amortization charges
174.30M
203.20M
131.74M
158.40M
EBITDA
3.35B
3.61B
3.52B
2.89B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps